Blood advances
Health-related quality of life after second-line Axi-cel in transplant-ineligible patients with large B-cell lymphoma.
Emilie Charton, Amélie Anota, Emmannuel Bachy, Guillaume Cartron, Francois-Xavier Gros, Franck Morschhauser, Lucie Obéric, Thomas Gastinne, Pierre Feugier, Remy Dulery, Catherine Thieblemont, Magalie Joris, Fabrice Jardin, Sylvain Choquet, René-Olivier Casasnovas
Published: 202610.1182/bloodadvances.2025018057
Abstract
The phase 2 ALYCANTE trial aimed to evaluate the investigator-assessed complete metabolic response at 3 months from the axi-cel infusion as a primary endpoint in patients with high-risk relapsed/refractory large B-cell lymphoma who are ineligible for…
Preview only. Read the full abstract at the source